Hospital Paul Brousse
- Address
- lock Available on a paid plan
Therapeutic Technologies
The department advances innovative therapeutic technologies by testing novel antibody combinations, targeted delivery systems, and emerging biologics to improve patient outcomes.
- Combination immunotherapy with chemotherapy
- Novel antibody‑drug strategies
- Advanced infusion therapies
- Safety monitoring of emerging biologics
Hospital Paul Brousse in Villejuif, France, supports 11 clinical trials led by 28 investigators, fostering cutting‑edge research in therapeutic innovation.
Digestive System Diseases
Researchers focus on liver‑related conditions, addressing diseases such as Primary Biliary Cholangitis and Alpha‑1 Antitrypsin Deficiency to alleviate symptoms and limit progression.
- Biliary tract cancer treatment
- Management of cholestatic itching
- Fibrosis reduction strategies
- Liver transplantation immunosuppression
The site’s multidisciplinary team conducts trials that integrate gastroenterology expertise with advanced diagnostic tools.
Neoplasms
The oncology program evaluates therapies for liver malignancies, including Hepatocellular Carcinoma and Advanced Biliary Tract Cancers, aiming to extend survival and improve quality of life.
- Immunotherapy plus TACE
- Neoadjuvant regimens for resectable tumors
- Dual checkpoint inhibition
- Targeted anti‑angiogenic combinations
Collaborative studies at Hospital Paul Brousse bring together surgical, radiologic, and medical oncology expertise.
Nutritional and Metabolic Diseases
Clinical investigations target rare metabolic liver disorders such as Urea Cycle Disorders and Crigler‑Najjar Syndrome, exploring cell‑based and gene‑silencing approaches.
- Cell‑based liver support therapies
- Metabolic correction via gene‑silencing
- Long‑term safety of stem‑cell infusions
- Metabolic disease monitoring
These studies integrate metabolic genetics with hepatology to address unmet therapeutic needs.
Behavioral Addictions
The psychiatry division investigates treatments for Behavioral Addictions such as gambling, sexual, and food compulsions, evaluating medications that reduce craving intensity.
- Craving reduction with adjunct medication
- Psychological outcome measures
- Addiction severity scales
- Integration with standard care
The trials aim to expand therapeutic options for patients struggling with compulsive behaviors.
General Clinical Research
A broad portfolio of multicentre investigations supports cross‑disciplinary studies, from safety profiling to biomarker discovery, enhancing overall clinical knowledge.
- Safety profiling across disease groups
- Biomarker discovery
- Patient‑reported outcome tools
- Health‑technology assessments
Hospital Paul Brousse leverages its extensive investigator network to conduct diverse and impactful research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 10 therapeutic areas and 15 of 100 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 90 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
- 1AstraZeneca AB3active
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Paul Brousse
lock Showing 1 of 59 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 100 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Oxaliplatin | 12 | Unknown | 2021-06-17 | 2026-02-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.